Testing the right target and right drug at the right stage
RA Sperling, CR Jack Jr, PS Aisen - Science translational medicine, 2011 - science.org
Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying
therapy is currently available. Recent disappointing trial results at the dementia stage of AD …
therapy is currently available. Recent disappointing trial results at the dementia stage of AD …
Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications
R Laforce, GD Rabinovici - Alzheimer's research & therapy, 2011 - Springer
In the past decade, positron emission tomography (PET) with carbon-11-labeled Pittsburgh
Compound B (PIB) has revolutionized the neuroimaging of aging and dementia by enabling …
Compound B (PIB) has revolutionized the neuroimaging of aging and dementia by enabling …
Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
F Hoffmann, B Neuroscience, B Deptula, X Yoo… - 2011 - jamanetwork.com
Background: Gantenerumab is a fully human anti-A monoclonal antibody in clinical
development for the treatment of Alzheimer disease (AD). Objectives: To investigate whether …
development for the treatment of Alzheimer disease (AD). Objectives: To investigate whether …
Alzheimer's association prompts FDA to broaden trials
KJ Bender - Psychiatric Times, 2011 - go.gale.com
The Alzheimer's Association announced in July that the FDA had accepted its
recommendations to modify exclusion and monitoring criteria for clinical trials of agents that …
recommendations to modify exclusion and monitoring criteria for clinical trials of agents that …
[引用][C] Amyloid imaging in the differential diagnosis of dementia: review and potential clinical
R Laforce, GD Rabinovici - Alzheimer's research & therapy, 3 (6), 2011